semaglutide alzheimer's trial AAN 2026 AAN 2026 - Results from

Summary Integrating emerging mechanistic and clinical observations, this review synthesizes current evidence from a metabolic flux perspective

Explore 23andMes new GLP-1 service and the revenue potential of compounded medications, plus key risks and industry insights.

Semaglutide side effects for weight loss include nausea, vomiting, diarrhea, & potential serious reactions

Most Insured Adults Still Have to Pay at Least Part of the Cost of GLP-1 Drugs

Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m